Bioxytran Turns Science into Everyday Wellness with Launch of Its First Two Nutraceutical Products 


Company applies its carbohydrate-chemistry expertise to consumer wellness with a post-meal blood sugar supplement and an immune support supplement 

Boston, Mass.,, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTCQB: BIXT) ("Bioxytran" or the "Company"), a clinical-stage biotechnology company developing platform technologies spanning Glycovirology, hypoxia, and degenerative diseases, today announced the launch two nutraceutical products: A-SUQAR, a supplement formulated to help maintain healthy blood sugar levels after meals, and V-LO, a supplement formulated to support healthy immune function. These statements have not been evaluated by the Food and Drug Administration, and the products are not intended to diagnose, treat, cure, or prevent any disease. 

The launch marks Bioxytran's expansion beyond its pharmaceutical pipeline into the consumer wellness market. A-SUQAR and V-LO are available beginning immediately at https://bioxytran.myshopify.com/ 

"For years, our team has worked on complex therapeutics for critical care and infectious diseases. Today we are bringing that same science directly to people's doorsteps," said David Platt, Ph.D., Chief Executive Officer of Bioxytran. "Our entry into nutraceuticals is driven by a simple principle: apply rigorous scientific standards to everyday health. We have held these products to the same diligence we apply to our drug programs, so consumers get a high-quality, science-backed supplement they can trust." 

The Products 

A-SUQAR – Metabolic Support. A-SUQAR is designed to help maintain healthy blood sugar levels after meals. It works by slowing the breakdown and absorption of dietary sugars in the intestine, supporting healthy metabolism and balanced energy throughout the day. 

V-LO – Immune Support. V-LO is formulated to support the body's natural immune defenses, helping people stay strong and resilient through the seasons. 

Built on Safety and Quality 

Both products draw on Bioxytran's expertise in complex carbohydrate chemistry and are formulated with ingredients that are Generally Recognized as Safe (GRAS). The products are manufactured in a certified facility and were tested by third independent party. 

Message to Shareholders and Friends 

"Our shareholders and friends, are the backbone of Bioxytran," said Dr. Platt. "We believe the best way to show the value of our work is to experience it firsthand. I invite you to try these products and make them part of your everyday routine. Thank you for your continued faith in Bioxytran. We look forward to sharing more updates on our progress." 

About Bioxytran, Inc. 

Bioxytran, Inc. (OTCQB: BIXT) is a clinical-stage biotechnology company developing platform technologies spanning Glycovirology, hypoxia, and degenerative diseases. The Company is now also applying its scientific expertise to high-quality nutraceutical products. For more information, visit www.bioxytraninc.com. 

Forward-Looking Statements 

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the launch, availability, market acceptance, and potential benefits of the Company's nutraceutical products and the Company's growth. Words such as "believe," "expect," "intend," "plan," "may," "will," and similar expressions identify forward-looking statements. These statements are based on current expectations and involve risks and uncertainties, including risks related to manufacturing and supply, consumer demand, competition, regulatory requirements applicable to dietary supplements, and the Company's ability to fund its operations. Actual results may differ materially. Additional risks are described in the Company's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Bioxytran undertakes no obligation to update any forward-looking statement, except as required by law. 

Contact 

David Platt, Ph.D. Chief Executive Officer Bioxytran, Inc.

75 Second Avenue, Needham, MA 02494

617-454-1199 

info@bioxytraninc.com 

 www.bioxytraninc.com 

###


GlobeNewswire